Dose-Response Improvements in Glycemic Control and Body Weight Reductions with Hm11260c, A Once-Weekly Glp-1 Receptor Agonist with Liraglutide As Reference, in Type 2 Diabetes (T2dm)
DIABETES（2015）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要
DIABETES（2015）